Castle Creek Biosciences (also known as Castle Creek Pharma) is a company that develops and commercializes gene therapies for patients with rare and serious genetic diseases. Its gene therapy candidate, FCX-007 treats recessive dystrophic epidermolysis bullosa (RDEB), the most severe and debilitating form of epidermolysis bullosa (EB). Castle Creek also advances clinical research evaluating a diacerein topical ointment, CCP-020, for the treatment of epidermolysis bullosa simplex (EBS) and other forms of EB.